Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02767804
Recruitment Status : Active, not recruiting
First Posted : May 10, 2016
Last Update Posted : January 31, 2022
Information provided by (Responsible Party):
Xcovery Holding Company, LLC